BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,140 filers reported holding BAXTER INTL INC in Q4 2021. The put-call ratio across all filers is 1.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $159,036 | -10.4% | 4,214 | +8.2% | 0.02% | -5.3% |
| Q2 2023 | $177,502 | +15.2% | 3,896 | +2.6% | 0.02% | +5.6% |
| Q1 2023 | $154,087 | +4.7% | 3,799 | +31.5% | 0.02% | 0.0% |
| Q4 2022 | $147,201 | +5.1% | 2,888 | +11.0% | 0.02% | -25.0% |
| Q3 2022 | $140,000 | -19.5% | 2,601 | -3.9% | 0.02% | -17.2% |
| Q2 2022 | $174,000 | -15.5% | 2,706 | +1.7% | 0.03% | -9.4% |
| Q1 2022 | $206,000 | -13.1% | 2,660 | -3.6% | 0.03% | -11.1% |
| Q4 2021 | $237,000 | +383.7% | 2,758 | +349.2% | 0.04% | +176.9% |
| Q3 2021 | $49,000 | -2.0% | 614 | -0.6% | 0.01% | +18.2% |
| Q2 2021 | $50,000 | -5.7% | 618 | -1.1% | 0.01% | -8.3% |
| Q1 2021 | $53,000 | -3.6% | 625 | -8.5% | 0.01% | -7.7% |
| Q4 2020 | $55,000 | +3.8% | 683 | +2.9% | 0.01% | -13.3% |
| Q3 2020 | $53,000 | -7.0% | 664 | -0.3% | 0.02% | -11.8% |
| Q2 2020 | $57,000 | -12.3% | 666 | -17.1% | 0.02% | -32.0% |
| Q1 2020 | $65,000 | -31.6% | 803 | -29.2% | 0.02% | -24.2% |
| Q4 2019 | $95,000 | -5.0% | 1,134 | -1.0% | 0.03% | -13.2% |
| Q3 2019 | $100,000 | +7.5% | 1,146 | +0.5% | 0.04% | +5.6% |
| Q2 2019 | $93,000 | -6.1% | 1,140 | -7.2% | 0.04% | -7.7% |
| Q1 2019 | $99,000 | +59.7% | 1,228 | +29.5% | 0.04% | +25.8% |
| Q4 2018 | $62,000 | – | 948 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |